The appointment of our newest board members, Henry McKinnell, Ph.D., Tony Gibney, and Francisco Leon, MD, Ph.D. marks a pivotal moment for LAPIX. Their impressive collective backgrounds in biotech, finance, and immunology will be invaluable as we move LPX-TI641 towards Phase II and continue on our mission to develop cures for #AutoimmuneDiseases. https://brnw.ch/21wGNgi
关于我们
LAPIX Therapeutics Inc. is a Boston, MA-based company in the biopharma sector, focused on developing novel, orally bioavailable immune system restoration therapies, including immune tolerance restoration therapy for autoimmune diseases, immune tolerance induction therapies for gene therapy and enzyme replacement therapy, and immune function restoration therapies for oncology.
- 网站
-
https://www.lapix.com
LAPIX Therapeutics的外部链接
- 所属行业
- 制药业
- 规模
- 2-10 人
- 总部
- Boston，Massachusetts
- 类型
- 私人持股
- 创立
- 2019
- 领域
- Immuno-oncology、Tolerance Induction、Auto-immune Disorders、Gene Therapy 和Enzyme Replacement Therapy
地点
-
主要
获取路线
451 D St
707
US，Massachusetts，Boston，02210
LAPIX Therapeutics员工
动态
-
Today marks an important milestone for LAPIX and those living with #MultipleSclerosis and other autoimmune conditions, as the first human participants have received LPX-TI641 as a part of our Phase I #ClinicalTrial. Read more about this significant update here: https://brnw.ch/21wEdXf
-